Evidence map›Paper›PMID 41634268›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

The evolution of cellular-based immunotherapy in the treatment of gastric cancer: an overview of clinical trials.

Lang Wu, Jasur Rizaev, Khaled Fahmi Fawy, Mustafa Jawad Kadham, Nabieva Dildora, Shakhlokhon Kurbanova, Zamira Atamuratova, Asilbek Dauletbaev, Natrayan Lakshmaiya, Raed Fanoukh Aboqader Al-Aouadi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lang WuDazhou Vocational College of Chinese Medicine, Dazhou, China.
Jasur RizaevDepartment of Public Health and Healthcare Management, Rector, Samarkand State Medical University, 18, Amir Temur Street, Samarkand, Uzbekistan.
Khaled Fahmi FawyResearch Center for Advanced Materials Science (RCAMS), King Khalid University, P.O. Box 9004, 61413, Abha, Saudi Arabia.
Mustafa Jawad KadhamAl-Farahidi University, Baghdad, Iraq.
Nabieva DildoraDepartment of Faculty and Hospital Therapy, Tashkent State Medical University, 100109, Tashkent, Uzbekistan.
Shakhlokhon KurbanovaDepartment of Psychology and Medicine, Mamun University, Khiva, Uzbekistan.
Zamira AtamuratovaDepartment of Pedagogy and Psychology, Urgench State University, Urgench, Uzbekistan.
Asilbek DauletbaevDepartment of Chemistry and Biology, Kimyo International University, Tashkent, Uzbekistan.
Natrayan LakshmaiyaDepartment of Research and Innovation, Saveetha School of Engineering, SIMATS, Chennai, Tamil Nadu, India.
Raed Fanoukh Aboqader Al-AouadiCollege of Medicine, Al-Ayen Iraqi University, Nasiriyah, Thi-Qar, Iraq. raed.fanoukh@alayen.edu.iq.ORCID http://orcid.org/0009-0000-7543-4020

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite advances in patients' healthcare, gastric cancer remains a major health concern around the world with a high annual incidence rate and mortality. This highlights the urgent need to develop more effective therapeutic strategies, particularly for patients in advanced stages of the disease. In the recent decade, cellular-based immunotherapy has achieved remarkable successes in various hematologic malignancies and solid tumors. Nonetheless, until now, no cellular-based immunotherapy has been approved for GC patients. This review aims to provide a holistic view of the current state of cellular-based immunotherapy for GC, its existing bottlenecks, and future directions to harness the potential of cellular-based immunotherapy for GC treatment. In this regard, we explore clinical trials of various types of cellular-based immunotherapy, including chimeric antigen receptor (CAR)-engineered cell therapy, T cell receptor (TCR)-engineered T cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, cytokine-induced killer (CIK) cell therapy, and dendritic cell (DC) vaccines. For each type of cellular-based immunotherapy, we discuss existing roadblocks to successful treatment and explore potential solutions that may improve efficacy, including novel targets, combination approaches, and biomarker-driven patient selection.

Indexed as

ImmunotherapyImmunotherapy, AdoptiveStomach NeoplasmsCancer VaccinesClinical Trials as TopicCytokine-Induced Killer CellsDendritic CellsHumansCancer VaccinesCellular-based immunotherapyClinical trialsGastric cancerImmunotherapyStomach cancer

Identifiers

PMID41634268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.